Biohaven (NYSE:BHVN) Cut to “Sell” at Wall Street Zen

Biohaven (NYSE:BHVN) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other equities analysts have also issued reports on BHVN. HC Wainwright restated a “neutral” rating and set a $10.00 target price on shares of Biohaven in a research report on Thursday, September 10th. TD Cowen restated a “buy” rating on shares of Biohaven in a research report on Wednesday, August 26th. Citigroup restated a “buy” rating on shares of Biohaven in a report on Friday, September 18th. Robert W. Baird set a $48.00 target price on shares of Biohaven in a report on Thursday, October 22nd. Finally, Royal Bank Of Canada lifted their target price on Biohaven from $19.00 to $22.00 and gave the stock a “sector perform” rating in a report on Friday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Biohaven presently has an average rating of “Moderate Buy” and a consensus target price of $20.80.

Biohaven Trading Up 3.8%

Shares of BHVN opened at $14.42 on Friday. The stock has a market cap of $2.18 billion, a PE ratio of -3.74 and a beta of 1.36. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 21.23. Biohaven has a twelve month low of $7.48 and a twelve month high of $18.24. The business’s 50-day moving average price is $13.61 and its 200-day moving average price is $12.31.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). On average, equities analysts forecast that Biohaven will post -3.05 EPS for the current fiscal year.

Institutional Trading of Biohaven

Hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC lifted its holdings in Biohaven by 1,145.9% in the first quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock worth $148,214,000 after acquiring an additional 16,127,247 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Biohaven during the 2nd quarter worth $196,574,000. Jupiter Topco LLC purchased a new position in shares of Biohaven during the second quarter valued at approximately $127,852,000. Stempoint Capital LP purchased a new position in shares of Biohaven during the first quarter worth about $13,489,000. Finally, Bank of America Corp DE purchased a new stake in shares of Biohaven in the 2nd quarter worth about $21,990,000. 88.78% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Biohaven

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: Biohaven says a pivotal Phase 3 trial of BHV-1300 for Graves’ disease is underway and presented three research posters at the American Thyroid Association meeting. The program could address a disease with few recent treatment advances, though trial progress is not a guarantee of success. Biohaven Graves’ disease Phase 3 and ATA announcement
• Positive Sentiment: HC Wainwright raised several future EPS estimates, including narrowing its projected losses for 2026–2029 and forecasting positive EPS in 2030. These revisions may bolster expectations for longer-term financial improvement.
• Positive Sentiment: A separate report says a Morgan Stanley analyst expects BHVN shares to rise, adding a favorable analyst signal; the article headline does not provide the rationale or target. Morgan Stanley analyst outlook
• Negative Sentiment: Despite its improved forecasts, HC Wainwright maintained a Neutral rating and a $10 price target, below the recent share price—suggesting that the analyst sees downside relative to current levels.

About Biohaven

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.